Table 1.
Intra-VTA pretreatment group |
Infusions/6-h Session (±S.E.) |
Responses/2-h Session (±S.E.) |
|
---|---|---|---|
SA Day 1 | SA Day 14 | Last Ext Day | |
Bicuculline (1 ng/side) |
83.75 (±8.66) | 92.75 (±14.07) | 10.38 (±1.24) |
Bicuculline (10 ng/side) |
79.00 (±7.57) | 96.00 (±11.48) | 14.57 (±3.46) |
Bicuculline (20 ng/side) |
61.38 (±7.80) | 83.00 (±17.21) | 12.50 (±1.76) |
2-hydroxysaclofen (0.2 µg/side) |
70.80 (±3.81) | 86.4 (±5.56) | 10.20 (±1.56) |
2-hydroxysaclofen (2 µg/side) |
72.22 (±3.27) | 82.44 (±4.23) | 6.22 (±1.54) |
Data represent infusions/6-h session (±S.E.) on days 1 and 14 of self-administration and responses/2-h session (±S.E.) during the final extinction session prior to starting reinstatement testing in separate groups of rats tested for effects of intra-VTA bicuculline (1, 10, or 20 ng/side) or 2-hydroxysaclofen (0.2 or 2 µg/side) on shock and CRF-induced reinstatement.